Fig. 4From: A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus – clinical significance and possible mechanisms: a case reportDetailed clinical course after September 2016. After the initiation of regimen ⑪ (sdpBRMd-CAM800), stringent complete response was obtained and is still maintained with regimen ⑫ (sdpBRedRMd-CAM800) as of October 2017. Myeloma cells disappeared from BM and hyperdiploidies also disappeared. Regimen ⑨ (sdpBD-CAM800) was also effective and the level of FLC-λ was depressed to normal range, but this treatment could not be continued due to aggravation of diabetes mellitus. BD Bor-Dex, BM bone marrow, BR Bor-Revlimid (lenalidomide), CAM clarithromycin, FLC free light chain, Md minimized dose, NCC nucleated cell count, PC plasma cell, PD pomalidomide-Dex, Red reduced dose, sdp short dosing-period, VAD vincristine, adriamycin, and DexBack to article page